A Journal of Perinatology study linked NNNS‑II neurological profiles to pharmacologic treatment trajectories among infants exposed prenatally to opioids, providing a potential tool to stratify withdrawal management and tailor interventions for neonatal abstinence syndrome. In contrast, a UK randomized trial found no additional clinical benefit from surfactant therapy in infants with severe bronchiolitis requiring mechanical ventilation, challenging off‑label use of surfactant in this population and prompting calls to refocus resources on alternative respiratory supports and evidence‑based protocols.